LGMN and Alzheimer disease: Increased levels of C/EBPβ contribute to the development of AD pathologies by partially enhancing AEP expression30, which acts as δ-secretase and then cleaves both APP and Tau at N585 and N368 residues, respectively, resulting Aβ production and Tau aggregation.